Luyan Pharma Co., Ltd. reports **CNY 16.18 billion in sales and revenue** for the nine months ended September 30, 2026. This marks a slight increase from the **CNY 15.86 billion** recorded in the same period the prior year. The company provides financial updates on its pharmaceutical business performance.
Luyan Pharma Co., Ltd. (XSEC: 002788) has been included in the S&P Global BMI Index. The index tracks large- and mid-cap companies across emerging markets, reflecting its growing market presence and investor recognition.
Luyan Pharma Co., Ltd. reports **CNY 10.58 billion in sales** for the first half of 2026, up from CNY 10.40 billion in the same period last year. The company’s net income declines to **CNY 143.01 million**, down from CNY 154.53 million year-over-year. The earnings update covers the half-year period ending June 30, 2026.
Luyan Pharma Co., Ltd. reports first-quarter 2026 sales of **CNY 5.35 billion**, up from **CNY 5.17 billion** in the same period last year. The company’s revenue matches its sales figure, reflecting continued growth in its financial performance for the quarter ended March 31, 2026.
